Biotechnology
News Category
Creative Biolabs Advances Neurodegeneration Research with iPSC Models
Creative Biolabs offers advanced iPSC-derived neuronal models to help researchers overcome limitations of traditional animal models and human tissue s...
Helus Pharma Surpasses 86% Enrollment in Phase 3 APPROACH Trial for Major Depressive Disorder
Helus Pharma announced that its Phase 3 APPROACH trial evaluating HLP003 for major depressive disorder has surpassed 86% enrollment, keeping the compa...
Onco-Innovations Engages Nanosoft to Advance ONC010 Development
Onco-Innovations has partnered with Nanosoft Polymers to support the manufacturing and formulation development of its lead nanoparticle-based PNKP inh...
Onco-Innovations Targets Next-Generation DNA Damage Response Cancer Therapies with ONC010(TM)
Onco-Innovations Limited advances a nanoparticle-encapsulated PNKP inhibitor into a $7 billion DDR market, with preclinical success and strategic part...
Quantum BioPharma's Lucid-MS Targets Myelin Repair in Multiple Sclerosis, Advancing to Phase 2 Trials
Quantum BioPharma's novel drug candidate Lucid-MS, which directly targets myelin sheath repair, is preparing for phase 2 clinical trials, offering a p...
Next-Generation DNA Repair Inhibitors Poised to Capture Billions as Oncology Market Expands
The emerging field of DNA Damage Response inhibitors, beyond established PARP inhibitors, represents a multibillion-dollar opportunity in oncology, wi...
Quantum BioPharma Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Quantum BioPharma is advancing Lucid-MS, a first-in-class drug candidate that directly protects the myelin sheath in multiple sclerosis, toward Phase ...
Cancer Nanomedicine Advances as Onco-Innovations Targets Scalability and Regulatory Readiness
Onco-Innovations' ONC010 combines a PNKP inhibitor with a polymer nanodelivery system to improve tumor targeting and tolerability, with recent manufac...
VERAXA Biotech Advances BiTAC-ADC Platform, Reports New Preclinical Data for Selective Cancer Cell Targeting
VERAXA Biotech AG (NASDAQ: VRXA) has released in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating selective activity against brea...
VERAXA Biotech Reports Positive Preclinical Data for BiTAC-ADC Platform, Seeks Partnerships at BIO 2026
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, showing selective cancer cell destruction, as it prepares to p...
Veraxa Biotech Expands Heidelberg R&D Facilities to Advance Oncology Pipeline
Veraxa Biotech's expansion of its Heidelberg R&D facilities signals a strategic push to move its BiTAC-based cancer therapies from discovery toward ea...
Lexaria Begins Dosing in Human Study Evaluating Oral Semaglutide Formulations Against Wegovy
Lexaria Bioscience has initiated a 5-week human pilot study testing two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablet...
Researchers Warn Against Overuse of Antibiotic Prophylaxis Amid Resistance Concerns
A new publication highlights the risks of antibiotic prophylaxis in driving antimicrobial resistance, urging medical caution and suggesting diagnostic...
Onco-Innovations Featured in BioMedWire Editorial on Emerging DNA Repair Inhibitors
Onco-Innovations Limited is highlighted in a BioMedWire editorial discussing the growing market for next-generation DNA Damage Response inhibitors, wi...